SUNDAY, NOVEMBER 3 MAIN TRAINING COURSES - eurogin

S U N DAY, N O V E M B E R

3

MAIN TRAINING COURSES The main training courses are designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV-related diseases in external genitalia and head & neck. Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

MTC 1 Break HPV11:00 infection Coffee - 11:30and diseases: the global view

Auditorium

Chair: S. Franceschi MTC 1-1 The burden of HPV-associated diseases

8:30 - 10:00 S. Franceschi

MTC 1-2 Epidemiology of HPV infection and related cancers - cervix vs. head & neck L. Alemany

France Spain

MTC 1-3 Natural history: current knowledge and perspectives

N. Wentzensen USA

MTC 1-4 HPV life cycle – an overview

J.

Doorbar

UK

Discussion

Coffee Break 10:00 - 10:30

MTC 2

Current standards for cervical cancer control: screening and vaccination, practices and challenges

Auditorium 10:30 - 12:15

Chair: X. Bosch MTC 2-1 HPV screening strategies: new evidence

J

MTC 2-2 HPV screening: current and future perspectives

P. Snijders

The Netherlands

MTC 2-3 HPV vaccines: update on efficacy, impact and safety profile

S. Garland

Australia

UK

MTC 2-4 HPV vaccines: implementation and experiences, strengths and weaknesses P. L. Lopalco

Sweden

MTC 2-5 WHO HPV vaccines recommendations

Switzerland

Discussion

14

Cuzick

S. Wang

S U N DAY,

N OV E M B E R

3

O R A L C O M M U N I CAT I O N S OC 1

Molecular markers

Sala Verde

Chair: P. Snijders

8:30 – 10:00

OC 1-1 Methylation of the HPV16 upstream regulatory region in relation to

HPV physical status in tonsillar and anal cancer OC 1-2 Integration and methylation status of E2-binding sites in HPV 16

in vulvar and vaginal carcinoma.

E. Prigge

Germany

G. Lillsunde-Larsson Sweden

OC 1-3 Methylation of viral and host genes in HPV-16 associated cervical lesions K. Louvanto

Canada

OC 1-4 Discovery of new methylation markers to improve early detection

of high-grade cervical intraepithelial neoplasia (CIN2/3)

A. Boers

The Netherlands

OC 1-5 HPV manipulation of the SUMO pathway

S. Chiocca

Italy

OC 1-6 Clinical validation of P16INK4a/KI-67 for the use in rotinely stained smears

S. Tiews

Germany

OC 1-7 Detection and quantification of HPV E7 oncoproteins in cervical smears

P. Jansen-Dürr Austria

OC 1-8 Development of a robust immunofluorescence technique to detect

HPV E4 protein in liquid based cytology (LBC) samples

R. Devine

UK

A. King

The Netherlands

X. van Ostade

Belgium

J.

Portugal

OC 1-9 Genetic variability in the major capsid L1 protein of human

papillomavirus type 16 (HPV16) in the Netherlands OC 1-10 Proteomic analysis of the cervicovaginal fluid leads to identification

of biomarkers for cervix cancer OC 1-11 MIR-125B expression in HPV infection and cervical cancer development:

Ribeiro

a potential biomarker Discussion


OC 2

Epidemiology (1) and pathogenesis of cervical and vulvar cancer Sala Verde Chair: A. Antilla

10:30 – 12:15

OC 2-1 Incidence of potentially HPV-related cancer in Germany

- an analysis using nationwide cancer registry data.

N. Buttmann

Germany

Y. Motoki

Japan

B. Jackson

USA

R. Ojha

USA

A. Rositch

USA

OC 2-2 Trends in incidence of cervical cancer from 1985 to 2009

in Kanagawa, Japan OC 2-3 Community-based interventions and temporal changes in the

characteristics of black cervical cancer cases in a low-resource setting OC 2-4 Younger age distribution of cervical cancer incidence among survivors

of pediatric and young adult cancers in the United States OC 2-5 Increased age and race-specific incidence of cervical cancer

after correction for hysterectomy in the United States from 2000 to 2009 OC 2-6 Incidence trends of cervical cancer and high-grade cervical

intraepithelial neoplasia in Denmark, 1997–2011 OC 2-7 Mortality of non-participants in cervical cancer screening

B. Baldur-Felskov Denmark P. A. Dugué

Denmark

C. Penning

The Netherlands

J.

Wang

Sweden

OC 2-10 Cervical cancer in association with pregnancy

T. Radberg

Sweden

OC 2-11 Natural history of CIN2/3 in an HPV therapeutic vaccine study

M. Stoler

USA

OC 2-12 Role of HPV in the pathogenesis of VIN3 of the anterior fourchette

M. Hampl

Germany

OC 2-8 Lower socioeconomic status groups have an increased risk

of cervical cancer regardless of screen coverage OC 2-9 Cervical cancer screening in women ages 50-65:

impact on cancer risk after age 65

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30

YEARS OF RESEARCH AND PRACTICE

15

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Colposcopy

Limonaia

Chair: J.-C. Boulanger, A. Perino

8:30 – 10:00

OC 3-1 Performance of dynamic spectral imaging colposcopy in patients

with abnormal cytology or a positive hrHPV-test

J.

Louwers

The Netherlands

OC 3-2 Women’s preferences of dynamic spectral imaging colposcopy

M. Kocken

The Netherlands

OC 3-3 Impact of acetic acid on HPV testing using Hybrid Capture 2

A. Pina

Canada

C. Karrberg

Sweden

K. You

China

M. Jakobsson

Finland

OC 3-5 Punch biopsies and loop biopsies to exclude microinvasive cancer

in early pregnancy are safe procedures OC 3-6 Analysis of colposcopic multi-point biopsy of 539 patients diagnosed

with ASC-H in cervical cytology report and one year follow-up OC 3-7 Pain during colposcopy and cervical biopsies with or without

local anesthesia: preliminary results of a randomized trial Discussion


OC 4

The clinical value of HPV testing in the management of cervical diseases

Limonaia 10:30 – 12:00

Chair: P. Cristoforoni, A. Kaufmann OC 4-1 Persistent high-risk human papillomavirus infection and its role

in recurrence of cervical intraepithelial neoplasia

K. Iwaniec

Poland

S. Sorbye

Norway

D. Ejegod

Denmark

A. Siebers

The Netherlands

C. Gosvig

Denmark

S. Verhelst

Belgium

O. Kachalina

Russia

OC 4-2 HPV mRNA is more specific than HPV DNA in triage of women

with minor cervical lesions OC 4-3 Clinical and analytical evaluation of the Onclarity HPV assay TM

in women referred for colposcopy OC 4-4 Effectiveness of two strategies to triage equivocal and low-grade

screening results in the Netherlands: cytological follow-up with or without hrHPV testing OC 4-5 Role of human papillomavirus (HPV) testing and cytology

in the follow-up after conization OC 4-6 Changes in HPV specific viral load as prediction of histology outcome OC 4-7 New diagnosis and treatment of HPV-associated preinvasive

cervical neoplasia in the reproductive age Discussion

16

S U N DAY,

N OV E M B E R

3

P R AC T I CA L WO R K S H O P S The workshops are designed to meet leaders involved in cervical cancer prevention. These sessions enable the participants to share their experience with the experts in order to improve evidence-based practice.

PWS 1

HPV testing for decision-making in screening and management Chair: M. Arbyn


PWS 1-1 Age-specific screening strategies by settings and vaccination status

X. Bosch

Spain

PWS 1-2 Management of HPV+ / cyto-negative women

C. Meijer

The Netherlands

PWS 1-3 Management of ASCUS and LSIL women

M. Einstein

USA

PWS 1-4 Evidence for clinical applications of hrHPV testing

M. Arbyn

Belgium

Discussion

PWS 2 HPV vaccination: the critical issues and new developments

Auditorium

Chair: A. Kreimer

14:50 - 15:35

PWS 2-1 Introduction

A. Kreimer

USA

M. Jit

UK

PWS 2-3 Cross-protection and alternating doses schedules

M. Brisson

Canada

PWS 2-4 HPV infection in vaccinated young women

N. Schlecht

USA

PWS 2-2 New issues and indications:

their implications for optimal vaccine strategies

Discussion


PWS 3 Management of cervical diseases: translating research into practice


Chair: T. Wright PWS 3-1 How to optimize the risk management concept

T. Wright

USA

PWS 3-2 Ablation vs. excision: how to make the right decision

M. Sideri

Italy

PWS 3-3 New strategies for post-treatment surveillance

M. Cruickshank UK

Discussion

PWS 4 Announcing HPV infection: how to deal with the patient

Auditorium

Chair: A.-B. Moscicki

16:45 - 17:30

PWS 4-1 Transmission: genital vs. oral – practical issues

M. Goodman

USA

PWS 4-2 The risk of cervical cancer: what the patient should know

D. Harper

USA

PWS 4-3 Announcing HPV infection: how to deal with the patient

A. B.Moscicki

USA

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


17

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



HPV screening (1) Chair: D. Heideman

OC 5-1 Comparison of four HPV assays in a primary screening population

Sala Verde 14:00 – 15:35 C. Rygaard Denmark

OC 5-2 Evaluating the introduction of primary HPV DNA screening in England:

using a novel stochastic model of HPV disease progression

I.

Bains

UK

OC 5-3 Comparison of cytology and HPV genotyping strategies for the triage

of HPV-positive women: results from the CCCAST study

S. Isidean

Canada

R. Konno

Japan

C. Fedato

Italy

K. Shen

China

OC 5-4 Assessment of a 5-year cervical screening interval with HPV testing

and cytology in Japan OC 5-5 HPV-DNA test repeat after one year in women HPV+ and Pap-.

First results from two HPV-based cervical screening programmes. OC 5-6 The role of Cervista hrHPV test in cervical cancer screening,

a cross-sectional study of clinical accuracy in mainland China OC 5-7 Evaluation of the Cervista HPV A9 group in the triage of patients

with high-risk HPV-positive in population based cervical cancer screening from SHENCCAST II H. Du

China

OC 5-8 HPV genotyping carcinogenicity and optimizational secondary

screening after primary of human papillomavirus

G. Wang

China

OC 5-9 Comparison between cytology and HPV DNA testing - using the

Cobas 4800 system, in the context of primary screening for cervical cancer prevention. Preliminary results from a multicenter Greek study.

T. Katsamagkas Greece

OC 5-10 The benefit-harm frontier of different HPV primary screening strategies

for cervical cancer in Germany

G. Sroczynski

Austria


OC 6

Vaccines (1)

Sala Verde

Chair: B. Romanowski, M. Safaeian

16:00 – 17:30

OC 6-1 Two doses of quadrivalent HPV vaccine might be sufficient

when vaccinating preadolescents

C. Sauvageau

Canada

K. Pollock

UK

OC 6-2 Early effect of the HPV bivalent vaccine on high-risk HPV prevalence

and high-grade cervical abnormalities in Scotland

OC 6-3 Long-term effectiveness of quadrivalent HPV vaccine in the Nordic countries M. Nygård

Norway

OC 6-4 Long-term effectiveness of the quadrivalent HPV vaccine

against non-vaccine HPV types in men

S. Goldstone

USA

S. Mahmud

Canada

A. Leval

Sweden

O. Iversen

Norway

A.C. Jacquard

France

L. Barzon

Italy

F.

Belgium

OC 6-5 Effectiveness of the quadrivalent human papillomavirus vaccine

against cervical dysplasia in Manitoba, Canada OC 6-6 Dose effectiveness of the quadrivalent human papillomavirus vaccine:

a national cohort study OC 6-7 Long-term extension study of quadrivalent HPV vaccine in adolescents;

results through month 96 OC 6-8 Impact of the quadrivalent HPV vaccine on the incidence

of genital warts in France (EFFICAE study) OC 6-9 Evaluation of neutralizing and cross-neutralizing antibodies induced

by HPV prophylactic vaccines: an independent study OC 6-10 Cell-mediated immune response to the HPV-16/18 AS04-adjuvanted vaccine

in HIV-positive women in South Africa up to 12 months after vaccination

Thomas

OC 6-11 Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered

as a 2-dose or 3-dose schedule up to 4 years after vaccination

B. Romanowski Canada

OC 6-12 Long-term effectiveness, tolerability and immunogenicity

of quadrivalent HPV vaccine in men

18

J.

Palefsky

USA

S U N DAY,

N OV E M B E R

3

WAC C Fo r u m & h e a l t h e d u c a t i o n Benefits and limitations of increasingly informed patients The WACC Forum is organized by the Women Against Cervical Cancer (WACC) Network which represents more than 50 associations from many different countries working for the benefit of womens' health and involved in cervical cancer prevention. This conference gathers players in the public health education sector from a number of countries, to share experiences on effective communication and learning tools aimed to increase HPV disease awareness and patient education towards active prevention.

W1

WACC Forum

Limonaia

Chair: J. Smith, M. Steben

12:15 - 13:30

Lecture: results of a worldwide E-learning program on cervical cancer prevention

X. Bosch

Spain

W 1-2

Educating women for HPV screening

D. Harper

USA

W 1-3

Making clinical sense of the fauna of increasingly informed patients

M. Steben

Canada

W 1-4

Advocacy, acceptability

F.

W 1-5

Barriers to prevention

D. Salisbury

UK

W 1-6

Cervical Cancer-Free Coalition: moving from evidence to action

J.

USA

W 1-1

Martinon-Torres Spain Smith

Discussion

OC 7

WACC Forum Oral Communications

Limonaia

Chair: F. Martinon-Torres

13:30 – 15:30

OC 7-1 Information provided by Google on HPV vaccination: how trustworthy is it? J.

Cortes

Spain

E. Miyagi

Japan

D. Lepusic

Croatia

S. Hanley

Japan

K. D'Hauwers

The Netherlands

A. Dempsey

USA

S. Alder

Sweden

T. Agorastos

Greece

M. Grandahl

Sweden

C. Alberts

The Netherlands

OC 7-2 Web-based recruiting and survey on knowledge for cervical cancer

prevention among young Japanese women: a pilot study OC 7-3 Education for sexual responsible behavior among adolescents OC 7-4 Effect of educational intervention on HPV vaccine acceptance

in areas with low and high cervical screening coverage OC 7-5 Impact of education on and attitudes towards HPV and vaccination,

before and 6 years after the introduction of the vaccines. OC 7-6 Impact and acceptability of four different decision-tools

for HPV vaccination among college-aged women OC 7-7 Parental acceptance of human papillomavirus (HPV) vaccination

for daughters in a country with a high prevalence of HPV infection OC 7-8 Trends in HPV vaccination acceptance between 2005 and 2012 in Greece OC 7-9 Not the right time and not enough evidence; parents’ reasons

to decline HPV vaccination OC 7-10 HPV vaccine acceptability among mothers from various ethnic

backgrounds in Amsterdam, the Netherlands: a qualitative study

OC 7-11 Parental acceptance of HPV vaccination of their sons in four EU countries G. Mortensen

Denmark

OC 7-12 Understanding the needs of Australian diverse population groups

to increase adolescent HPV vaccination uptake.

M. Heffernan

Australia

M. Rebolj

Denmark

OC 7-13 The psychological impact of cervical intraepithelial neoplasia:

a systematic review Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


19

EUROGIN

20 1 3

S U N DAY,

N OV E M B E R


WAC C i n Ja p a n Jointly organized by PCAF (People’s Campaign Against Female cancer) and the Japanese Expert Board for the Eradication of Cervical Cancer. This session is aimed at reporting and evaluating activities for Women Against Cervical Cancer in Japan in order to share experience globally.

W2

WACC in Japan

Limonaia

Chair: N. Sakuragi, R. Konno, S. Garland

Recent trends in cervical cancer incidence and mortality in Japan

16:00 - 17:30 S. Hanley

Japan

Surveys of attitudes towards HPV vaccination and importance of cancer education in schools

S. Hanley

Japan

PCAF’s Shine campaign for publicizing current knowledge about cervical cancer

K. Sakuragi

Japan

HPV testing in cervical cancer screening and function-preserving surgery in cervical cancer treatment

N. Sakuragi

Japan

W 2-5

Asparadise - patient support group for gynecologic cancer survivors

S. Oshima

Japan

W 2-6

Activity of Japanese Expert Board for Eradication of Cervical Cancer for National immunization program and HPV screening

R. Konno

Japan

W 2-7

Activity of Japan Cancer Society

H. Konishi

Japan

W 2-8

Surveys of attitude for cervical cancer screening

M. Ito

Japan

W 2-9

Local activities in Yokohama city

E. Miyagi

Japan

A. Namai

Japan

W 2-1

Women Against Cervical Cancer in Hokkaido: primary prevention W 2-2 W 2-3

Women Against Cervical Cancer in Hokkaido: secondary and tertiary prevention W 2-4

W 2-10 Peer education for university students by Ribbon movement

Discussion: Challenges today and in the near future

20

3

OPENING CEREMONY S u n d a y, N o v e m b e r 3 Auditorium 19:00 - 20:30 WELCOME J. Monsonego (France) Message from the Presidents EUROGIN's contribution and proposals for the fight against HPV-associated diseases

G..Ronco (Italy) - M.Roy (Canada) The worldwide expertise: the EUROGIN Roadmap contribution S. Franceschi (France) The women's commitment: the WACC Foundation's efforts A. Singer (UK) - J. Smith (USA) Educational perspectives and translating research: the CME initiative J. Cortes (Spain) The Italian experience F. Carozzi (Italy) To the memory of Anne Szarewski J. Cuzick (UK) Opening Guest Lecture The squamocolumnar junction and cervical cancer prevention C. Crum (USA)

20:30 WELCOME RECEPTION at the Fortezza da Basso (Arsenale room)

M O N DAY, N O V E M B E R

4

MAIN SCIENTIFIC SESSIONS Main Scientific Sessions include keynote lectures providing a broad overview of the essential issues on cervical cancer prevention by the most prominent experts in their respective field.

MSS 1

HPV Screening (1) revisited

Auditorium

Chair: X. Bosch

8:00 - 9:30

MSS 1-1 Triage of women with negative cytology and positive high-risk HPV:

an analysis of data from the SHENCCAST* II/III studies

S. Goodrich

USA

T. Iftner

Germany

M. Schiffman*

USA

A. Virtanen

Finland

K. Louvanto

Canada

T. Wright

USA

MSS 1-2 Cross-sectional and longitudinal data on the comparison of APTIMA

and HC2 HPV assays in routine screening in Germany MSS 1-3 A prospective study of genotyping for the management of HPV-positive,

Pap-negative results MSS 1-4 Self-sample HPV-tests: effects in cervical cancer screening

attendance in Finland MSS 1-5 Implementing cervical cancer screening with HPV testing followed

by Pap triage in routine practice: the Montreal VASCAR project MSS 1-6 Risk of CIN3 after 3 years of follow-up in the ATHENA trial

Discussion

MSS 2 Vaccines (1): vaccination programs - lessons learned

Auditorium

Chair: P.-L. Lopalco, D. Salisbury MSS 2-1 Decision-making process in introduction of HPV vaccination

9:30 - 11:00 P.L. Lopalco

Sweden

MSS 2-2 Success stories in implementing HPV vaccination: the health economy issues D. Salisbury

UK

MSS 2-3 Implementation of HPV vaccination for males: Australia’s experience so far J.

Australia

Brotherton

MSS 2-5 Lessons learned to date from HPV vaccination programs

in developing countries

S. Wang

Switzerland

Discussion


* to be determined

22

M O N DAY,

N OV E M B E R

4


Recent advances on anal HPV-related diseases

Sala Verde

Chair: L. Siproudhis, P. Mullerat

8:00 – 9:30

OC 8-1 Parallels between anal and cervical intraepithelial lesions

- a prospective study OC 8-2 Anal high-risk HPV incidence among HIV-negative and HIV-positive MSM

M. Reis

Portugal

D. Van Santen

The Netherlands

L. Siproudhis

France

OC 8-3 Screening the anal dysplasia in HIV-positive patients:

how efficient is high-resolution anoscopy? OC 8-4 High prevalence of high grade anal intraepithelial neoplasia

A. de Pokomandy Canada

in women living with HIV, preliminary results of the EVVA study OC 8-5 Anal HPV integration and identification of other DNA viruses

in HIV-uninfected men who have sex with men

F.

Paolini

Italy

OC 8-6 Detection of high-risk HPV in men who have sex with men,

living with HIV: application of an automated real-time PCR test

A. Herrera Ortiz Mexico

Discussion

SCIENTIFIC SESSIONS SS 1

PREvention strategies for HPV-related Diseases In European CounTries (PREHDICT)

Sala Verde 9:30 - 11:00

Chair: J. Dillner, C. Meijer SS 1-1

Quality assurance for cervical cancer screening in Europe

M. Elfström

Sweden

SS 1-2

Modeling the effect of vaccination on HPV infection prevention

S. Vänskä

Finland

SS 1-3

Modeling data about the effect of vaccination and screening on cancer prevention

J.

Berkhof

The Netherlands

SS 1-4

New biomarkers in HPV screening

P. Snijders

The Netherlands

SS 1-5

Effect HPV screening on prevention of invasive cancer

G. Ronco

Italy

SS 1-6

Implementation policies and priority setting for the next years in EC countries: the CoheaHr project

C. Meijer

The Netherlands

Discussion

SS 2

Gynecologic 0ncology: what is new in the treatment of cervix cancer?

Limonaia 8:30 - 11:00

Chair: C. Haie-Meder, T. Maggino SS 2-1

Introduction

C. Haie-Meder

France

SS 2-2

What's new with positron emission tomography in cervical cancer

G. Bonardel

France

SS 2-3

Simple hysterectomy and sentinel node excision in cervical cancer

M. Roy

Canada

SS 2-4

New challenges in surgery of cervical cancers

T. Maggino

Italy

SS 2-5

Treatment of stages 1a and 2b of cervical cancers

J.

Spain

SS 2-6

Image-guided brachytherapy in cervical cancer

R. Pötter

Austria

SS 2-7

Radiotherapy and anti-HPV treatment

E. Deutsch

France

SS 2-8

Risk of premature delivery after treatment of CIN: due to treatment or due to CIN?

M. Cruickshank UK

Discussion

EUROGIN

20 1 3

HPV

Cortes

M. Roy (Canada) - T. Maggino (Italy) AT A CROSSROADS

- 30


23

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



HPV epidemiology (2)

Palazzo degli Affari Ground floor

Chair: I. Baussano, M. Goodman

8:00 – 11:00

OC 9-1 Prevalence of human papillomavirus infection

in a Kashmiri ethnic female population

M. Zargar

India

OC 9-2 High-risk urogenital HPV infections in Paramaribo, Suriname:

Prevalence and risk factors in an ethnically diverse population of women

J.

van der Helm The Netherlands

OC 9-3 Prevalence and distribution of human papillomavirus types

among Thai females in Bangkhayeng, Prathumthani province, Thailand

N. Phoolcharoen Thailand

OC 9-4 HPV infection in cervical and other cancers in Saudi Arabia:

implication for prevention and vaccination

G. Alsbeih

Saudi Arabia

M. Mollers

The Netherlands

K. Sundström

Sweden

H. Lewis

New Zealand

L. Bianchi

Italy

OC 9-5 Clustering of multiple HPV types across diverse risk populations

in the Netherlands; population- or type-specific? OC 9-6 Interaction between HPV types in squamous cervical neoplasia OC 9-7 Type-specific oncogenic HPV infection in high grade cervical disease

in New Zealand OC 9-8 Human papillomavirus multiple infections:

comparison between cytological and histological lesions OC 9-9 Association of smoking with high-risk HPV infection

in women undergoing cervical cancer screening in northern Greece

K. Chatzistamatiou Greece

OC 9-10 Prevalence and distribution of HPV genotypes

in squamous cell papilloma of the conjunctiva

M. Poljak

Slovenia

S. Matthijsse

The Netherlands

OC 9-11 Type-specific transmission probabilities and the role of

infection-induced immunity in the spread of HPV in the Netherlands OC 9-12 Prevalence of genital warts in specialists' practices in the Philippines

L. Buenconsejo Philippines

OC 9-13 Prevalence of genital warts in health care professional practices

in South Africa Discussion


24

M. Haffejee

South Africa

M O N DAY,

N OV E M B E R

4

C L I N I CA L S E S S I O N S The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

CS 1

Screening (2): molecular-based strategies for primary screening of cervical cancer

Auditorium 14:15 – 15:45

Chair: J. Dillner, A.-B. Moscicki CS 1-1

Gain in protection of cervical cancer with HPV screening: new evidences

G. Ronco

Italy

CS 1-2

Risk-based screening strategies

C. Meijer

The Netherlands

CS 1-3

Benefits and harm of HPV-based screening

A. Antilla

Finland

CS 1-4

Existing strategies and innovative intervention: HPV alone vs. co-testing

J.

Cuzick

UK

Dillner

Sweden

Which test for which screening? CS 1-5

- Pooled HPV DNA assays

J.

CS 1-6

- HPV genotyping assays

T. Wright

USA

CS 1-7

- HPV mRNA assays

M. Arbyn

Belgium

CS 1-8

- careHPV

A. Longatto-Filho Brazil

CS 1-9

- p16

F.

CS 1-10 - CINtec PLUS VUSA Screen

Carozzi

C. Meijer

Italy The Netherlands

Discussion

CS 2

Vaccines (2): HPV vaccination - what's new?

Auditorium

Chair: J. Paavonen, M. Stanley

15:45 – 17:00

CS 2-1

Introduction: current knowledge and the future

M. Stanley

UK

CS 2-2

Long-term registry-based follow-up

J.

Dillner

Sweden

CS 2-3

HPV vaccination and gender equity: direct and indirect benefits of vaccination of males

J.

Paavonen

Finland

CS 2-4

A community randomized phase IV vaccination trial on vaccination strategies: overview of deliverables

CS 2-5

Cost-benefits of HPV vaccination: new evidence

N. Van de Velde Canada

Discussion


EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


25

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


TRAINING SESSION TS 1

&

HN

HPV and the clinic: state of the art in HPV head & neck squamous cell cancer (HNSCC)

Sala Verde 14:15 - 16:00

Chair: H. Mehanna

Trends in the epidemiology and global burden of HPV+ and HPV- oropharyngeal cancer

H. Mehanna

UK

Use of cell-based models to investigate the role of HPV infection in oropharyngeal carcinogenesis

S. Roberts

UK

The combination of HPV and other biomarkers for prediction of clinical outcomes

T. Dalianis

Sweden

TS 1-4

Testing for HPV oropharyngeal cancer – pearls, pitfalls and progress

P. Snijders

The Netherlands

TS 1-5

Clinical trials of treatment de-intensification in favorable risk HPV-associated head & neck cancer

B. Burtness

USA

TS 1-1 TS 1-2 TS 1-3

TS 1-6

HPV associated oropharyngeal cancer – defining better treatment strategies D. Rischin

Australia

TS 1-7

Critical issues in selection of patients with oropharyngeal squamous cell carcinomas for treatment de-escalation trials

The Netherlands

R. Brakenhoff

Discussion panel - At which conditions will it be possible to modify the treatment? - Designs to suggest for treatment trials of HNSCC according to HPV status J.

Lacau St Guily France


&

HN

Scientific panel discussion: HPV and tobacco interactions – how do we sort it out? Chair: A. Chaturvedi, X. Castellsagué

SS 3-1

Epidemiologic associations of smoking, HPV infection and related cancer S. Franceschi

France

SS 3-2

Clinical aspects of HPV disease and smoking

M. Gillison

USA

SS 3-3

Molecular aspects of HPV and smoking in the carcinogenesis of head & neck cancers

R. Brakenhoff

The Netherlands

Panel discussion on reasons for inconsistent associations in the literature and study designs/strategies for addressing the question


26

Sala Verde 16:00 - 17:00

M O N DAY,

N OV E M B E R

4


Screening and prevention: new developments

Limonaia

Chair: M. Elfström, J.-J. Baldauf

14:15 – 16:00

OC 10-1 Assessment of HPV vaccination in general population

by comparing vaccination and screening data in Alsace-France. OC 10-2 Modelling strategies for cervical cancer screening: a systematic review

J.-J. Baldauf

France

D. Mendes

UK

W. Huh

USA

N. Veldhuijzen

The

S. Lönnberg

Norway

P. Barbarino

Italy

OC 10-3 Evaluating the cost-effectiveness of human papillomavirus (HPV)-based

cervical cancer screening strategies, including genotyping for HPV 16/18 OC 10-4 The lifetime risk of screen-detected hr-HPV or abnormal cytology

Netherlands OC 10-5 Risk stratification analysis for informed decisions on screening strategy OC 10-6 Cervical cancer screening based on primary high-risk HPV DNA testing

in Italy: first and second round performance indicators

OC 10-7 HPV4 vaccine adherence in a safety net population worsens as BMI increases D. Harper

USA

OC 10-8 Organization and quality control in cervical cancer prevention:

evidence from a Europe-wide survey

M. Elfström

Sweden

Discussion

OC 11

HPV in men: emerging issues

Limonaia

Chair: C. Pierce Campbell, C. Lacey

16:00 – 17:30

OC 11-1 Effectiveness of male condom in prevention of cervical neoplasia:

systematic review of longitudinal studies

M. Rebolj

Denmark

OC 11-2 Factors associated with the development of male external genital lesions: C. Pierce Campbell

the HIM study

USA

OC 11-3 High-risk anal human papillomavirus (HPV) types in Australian

homosexual men - patterns of infection

M. Poynten

Australia

J.

Australia

OC 11-4 High incidence and clearance of anal high-grade squamous

Intraepithelial lesions (HSIL) in homosexual men

Jin

OC 11-5 Anal and penile low-risk HPV infection in HIV-negative and HIV positive MSM C. Welling

The Netherlands

OC 11-6 Prevalence & correlates of unsatisfactory anal pap tests (UAPT)

in a community-recruited cohort of Australian homosexual men

D. Templeton

Australia

S. Mooij

The Netherlands

OC 11-7 Seroconversion after HPV infection and effect of antibodies

on subsequent HPV infection in HIV-negative and HIV-infected MSM Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


27

EUROGIN

20 1 3

HPV

M O N DAY,

AT A CROSSROADS

N OV E M B E R

4


Quality assurance programs of HPV testing


Chair: K. Cuschieri, E. Unger

14:15 - 15:00

SS 4-1

Disagreement between HPV assays in primary screening

J

SS 4-2

The evolving requirements for validation and QA of HPV tests for service

K. Cuschieri

UK

SS 4-3

API - Assay Performance Indicators: assessment and comparison of molecular HPV assay performance

J.

Denmark

WHO HPV LabNet: Shared international experience for improved HPV testing

E. Unger

SS 4-4

Bonde

Bonde

Denmark

USA

Discussion


HPV testing: methods & value


Chair: H. Cubie - J.-P. Bogers

15:00 – 17:10

OC 12-1 Detection of high-grade CIN by four HPV assays

in women with abnormal cytology

J.

OC 12-2 The value of viral load as a predictive marker OC 12-5 Clinical validation (VALGENT-2) of the LMNX genotyping kit HPV GP

targeting 14 hrHPVs and an internal control

OC 12-6 Testing for cervical dysplasia by vaginal lavage and E6 oncoprotein assay

– a pilot trial

OC 12-7 Evaluation of the RealTime high risk HPV assay

on self-collected cervicovaginal lavage samples

Junge

Denmark

J.-P.Bogers

Belgium

D. Geraets

The Netherlands

A. Krings

Germany

M. Jentschke

Germany

C. Payan

France

S. Pillet

France

P. Smits

The Netherlands

OC 12-8 Efficiency and cost effectiveness of an urine test

for human papillomavirus (HPV) detection in a new strategy for cervical cancer screening (the PAPU29 study)

OC 12-9 Evaluation of the CLART® HPV2 micro array assay

on seminal plasma samples

OC 12-10 Analytical comparison of the RealTime high-risk HPV with

Hybrid Capture II and GP 5+/6+ HR-HPV PCR on SurePath specimens

OC 12-11 Performance assessment of automated Hybrid Capture 2 : ®

QIAsymphony® DSP HPV Media Kit & Rapid Capture® System

A. Bunse-Grassman Germany

OC 12-12 Highly sensitive discrimination of high-grade cervical cytology

from normal cytology using “The Slideless Pap™” parameters and bioinformatics: a preliminary analysis

B. Patterson

USA

J.

Reiser

France

P. Neophytou

Cyprus

Anyplex™ II HPV28 assays on two different cervical collection media for HPV genotyping

S. Hantz

France

OC 12-3 Performance of Hybrid Capture using residual SurePath pellets

T. Wright

USA

J.

UK

OC 12-13 Urinary HPV testing as an alternative to the cervical smear

in cervical cancer screening: a pilot study in Maine et Loire

OC 12-14 European HPV DNA test External Quality Assurance Scheme (EHEQAS) OC 12-15 Comparison of INNO-LiPA HPV genotyping extra and seegene

OC 12-4 A comparison of the performance

of different HPV tests in ThinPrep vs SurePath

Discussion


28

Cuzick

T U E S DAY, N O V E M B E R

5

MAIN SCIENTIFIC SESSIONS MSS 3 HPV screening (2): new evidence-based guidelines

Auditorium

Chair: E. Franco, T. Wright MSS 3-1 Bias and pitfalls in cancer screening

E.

MSS 3-2 HPV-based screening guidelines in Europe

A.

MSS 3-3 The US Preventive Services Task Force recommendations in cervical cancer screeningW. MSS 3-4 The ACS/ASCCP/ASCP guidelines in cervical cancer screening

T.

MSS 3-5 The Canadian Task Force recommendations in cervical cancer screening

V.

8:00 - 9:30 Franco Canada Antilla Finland Huh USA Wright USA Mai Canada

Discussion

MSS 4 Cervical cancer control in Italy: screening and vaccination

Auditorium

Chair: F. Carozzi, A. Frega

9:30 - 11:00

MSS 4-1 Best practices in Italy to get a good vaccine coverage

P. Bonanni

Italy

MSS 4-2 HPV as primary screening: from research to practice

M. Zappa J. Cuzick

Italy UK

MSS 4-3 The clinician : towards the change in prevention

A. Perino S. Dexeus

Italy Spain

Italian

Workshop

Discussant: Discussant: Discussant:

Discussion

MSS 5 HPV and non-oropharyngeal cancers of the head & neck

Sala Verde

Chair: M. Gillison

8:00 - 9:30

MSS 5-1 Introduction

M. Gillison

USA

MSS 5-2 CDC data presentation

M. Goodman

USA

MSS 5-3 IOC data presentation

X. Castellsagué Spain

MSS 5-4 Serology associations data

M. Pawlita

Germany

S. Rajendra

Australia

MSS 5-5 Transcriptionally active HPV and the Barrett’s

metaplasia-dysplasia-adenocarcinoma sequence

&

HN

Discussion

SCIENTIFIC SESSIONS (H&N) SS 5

HPV infection in the oral cavity: new insights

Sala Verde

Chair: S. Syrjänen, T. Dalianis

9:30 - 11:00

SS 5-1

Oral HPV infection: epidemiology, transmission and risk factors

A. Chaturvedi

USA

SS 5-2

Oral HPV: mechanisms of infection, persistance and natural history

M. Gillison

USA

SS 5-3

Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study

S. Syrjänen

Finland

Oral HPV prevalence in youth in Sweden with and without voluntary vaccination

T. Dalianis

Sweden

SS 5-5

Why the tonsils are susceptible to HPV infection

S. Pai

USA

SS 5-6

Immune infiltration and hypoxia in oral-pharyngeal squamous carcinoma K. Oguejiofor

SS 5-4

&

HN

USA

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


29

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Vaccines (3): recent advances on prophylactic HPV vaccination

Limonaia

Chair: S. Garland

8:00 - 9:30

Overviews of HPV vaccination trials SS 6-1

- FUTURE trial

S. Garland

Australia

SS 6-2

- PATRICIA trial

J.

Finland

SS 6-3

- Costa Rica trial

A. Kreimer

USA

SS 6-4

Immunogenicity and efficacy of HPV vaccines based on fewer doses and administration

M. Safaeian

USA

Do we need a new HPV vaccine? What the economic model can tell us?

M. Jit

UK

SS 6-5

Paavonen

Discussion

SS 7

New trends on vaginal self-sampling

Limonaia

Chair: A. Lorincz, J. Belinson SS 7-1

Overview

A. Lorincz

UK

SS 7-2

Meta-analysis of the accuracy of HPV DNA testing using self-collected versus clinician-based sampling of cellular material to detect HG CIN

M. Arbyn

Belgium

SS 7-3

Self-sampling versus clinician sampling for use with the careHPV test

A. Lorincz

UK

SS 7-4

Self-sampling for non-attendees of screening in The Netherlands

D. Heideman

The Netherlands

SS 7-5

Mailed self-sampling intervention project among under-screened women in the United States A. Des Marais

USA

Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program

E. Östensson

Sweden

Triage strategies for women who test HPV positive on self-sampled material: post-hoc analysis of the PROHTECT-3A study

V. Verhoef

The Netherlands

HPV infection and cervical lesions over 18 months in physician - and self-collected specimens in female sex workers, Kenya

J.

USA

SS 7-6

SS 7-7 SS 7-8

Discussion


30

9:30 - 11:00

Ting

T U E S DAY,

N OV E M B E R

5


Late breakers communications


Chair: M. Brisson, S. Franceschi SS 8-1 SS 8-2 SS 8-3 SS 8-4 SS 8-5

SS 8-6 SS 8-7 SS 8-8

8:00 - 9:30

Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in adolescent girls aged 10–14 years: 7-year follow-up. T. Schwarz

Germany

Comparison of long-term immunogenicity of two prophylactic human papillomavirus (HPV) vaccines: final analysis of a Phase III trial

M. Einstein

USA

An overview of the 9-valent HPV L1 virus-like particle vaccine clinical development program

A. Luxembourg USA

Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women

E. Joura

Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old; comparison to women 16-26 years old

P. Van Damme Belgium

Immunogenicity and safety of a novel 9-valent HPV vaccine in girls 9-15 years of age compared to the quadrivalent vaccine


Safety and tolerability of a novel 9-valent HPV L1 virus-like particle vaccine in boys/girls age 9-15 and women age 16-26

A. Giuliano

USA

Molecular and immunocytochemical biomarkers in the triage of ASCUS/LSIL and HSIL cytology

P. Karakitsos

Greece

Austria

Discussion

SS 9

Therapeutic vaccines against HPV 16/18 infection – new developments


Chair: D. Harper SS 9-1

9:30 - 11:00

Introduction: Prevention and treatment of human papillomavirus 16/18 related cervical diseases

D. Harper

USA

SS 9-2

Role of HPV screening and management of the HPV16/18-infected women X. Bosch

Spain

SS 9-3

Biology of HPV infection and rationale for treatment prior occurence of cervical lesions

M. Stanley

UK

Phase I trial results with ProCervix vaccine in HPV 16 / 18 infected women with normal cytology


Evolution of HPV testing in the wake of new therapeutic vaccines

T. Iftner

Germany

Closing Remarks

D. Harper

USA

SS 9-4 SS 9-5


EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


31

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Biology - Immunology

Palazzo degli Affari Adua 1

Chair: M. Tommasino

8:00 – 9:30

OC 13-1 Role of naturally-acquired antibodies in new HPV infection and

pre-cancerous lesions: analysis of the control cohort of the PATRICIA study D. Rosillon

OC 13-2 Clonal CD4+ T cells cross-react with homologous L1-derived peptides

of high risk and low risk HPV types

OC 13-3 Characterization of the inflammatory infiltrate in human papillomavirus

associated cervical lesions

OC 13-4 HPV 16 E2-, E6- and E7-specific T-cell responses in children and their mothers OC 13-5 A new benchmark of the pre-vaccine seroprevalence

of HPV16 in the Netherlands

OC 13-6 Immune cell infiltration in relation to P16INK4a expression in cervical

intraepithelial neoplasia and cancer

OC 13-7 Naturally occurring FG loop variants of HPV31: implications for current

and next generation L1-based prophylactic vaccines

OC 13-8 High-Risk HPV51: L1 and L2 amino acid diversity and recognition

by antibodies elicited by natural infection

Belgium

T. Kube

Germany

M. Tacla

Brazil

A. Paaso

Finland

A. Vink

The Netherlands

M. Sauer

Germany

S. Bissett

UK

A. Godi

UK


Modeling - key issues in the field of HPV: how can models help our understanding?


Chair: M. Brisson, H. Berkhof SS 10-1 Background

9:30 - 11:00 M. Brisson

Canada

K. Looker

UK

SS 10-3 Model validity and credible projections: an insight from PREHDICT study

I.

Baussano

France

SS 10-4 Serotype replacement: second-guessing the clustering of HPV types

J.

Bogaards

The Netherlands

SS 10-5 HPV infections: herd effects following vaccination

S. Vänskä

Finland

T. Malagon

Canada

M. Jit

UK

SS 10-2 The interaction between HIV and HPV infections:

how relevant is it for public health?

SS 10-6 Inequalities in cervical cancer: role of vaccine herd immunity

in protecting women with low screening participation

SS 10-7 HPV vaccination in developing countries:

assessing the value of vaccines across the world

Discussion

SS 11

HPV genotyping, recent advances

Palazzo degli Affari First floor

Chair: S. De Sanjosé, J. Smith SS 11-1

Genotype distribution in penile and vulvar cancers within ICO studies

L. Alemany

Spain

SS 11-2

The value of HPV genotyping in self-samples of screening non-attendees

P. Snijders

The Netherlands

SS 11-3

Differences in carcinogenicity of high-risk HPV types: inferences from cross-sectional meta-analyses

G. Clifford

France

The distribution of 12 high-risk HPV types detected in high-grade CIN, VIN and VaIN lesions from women 16-45 years of age

E. Joura

Austria

HPV type distribution and age-specific incidence of external genital lesions in the HIM study

D. Ingles

USA

Development and validation of a new HPV genotyping assay based on next generation sequencing

J.

USA

SS 11-4 SS 11-5 SS 11-6

Discussion


32

9:30 - 11:00

Belinson

T U E S DAY,

N OV E M B E R

5

C L I N I CA L S E S S I O N S CS 3

Performance of cervical colposcopy: a debate

Auditorium

Chair: J. Monsonego, A. Singer

13:00 – 15:00

Applying the concept of equal risk=equal management to cervical colposcopy and biopsy?

N. Wentzensen USA

CS 3-2

Accuracy of colposcopy - data from the FUTURE trial Discussant:

M. Stoler S. Dexeus

USA Spain

CS 3-3

CIN2: reality or myth? Discussant:

A. Moscicki M. Sideri

USA Italy

CS 3-4

The value of random biopsies Discussant:

R. Pretorius J. Bornstein

USA Israel

CS 3-5

New nomenclature by IFCPC Discussant:

J. Bornstein A. Perino

Israel Italy

CS 3-6

Non-ablative treatment of CIN/VIN Discussant:

M. Einstein USA M. Cruickshank UK

CS 3-7

New methods of teaching colposcopy in the electronic age Discussant:

A. Singer J. Cortes

UK Spain

CS 3-8

Quality control in colposcopy Discussant:

M. Roy A. Singer

Canada UK

CS 3-1


CS 4

Clinical value of HPV testing

Auditorium

Chair: J. Cuzick, P. Snijders CS 4-1

17:00 – 18:00

Effects of persistence and HPV type on the long-term risk of CIN3+ following HPV infection: 10 year follow-up of women in the artistic trial

J.

CS 4-2

Role of mRNA testing in triage of women with minor cytological abnormalities F.

CS 4-3

2012 consensus guidelines for the management of women with abnormal screening tests and CIN & AIS: a risk-based approach

CS 4-4

Peto

UK

Verdoodt

Belgium

W. Huh

USA

Earlier detection of high-grade CIN and overdiagnosis with HPV vs. cytology G. Ronco

Italy

Discussion


Update on HPV testing methods

Auditorium

Chair: T. Iftner, C. Clavel

18:00 - 19:15

SS 12-1 The Scottish Test of Cure Study (STOCS-H) – A multi-platform

comparison of HPV tests in a post-treatment context

H Cubie

UK

SS 12-2 Comparison of HPV testing methods

T. Iftner

Germany

SS 12-3 HPV testing in self-sampling

A. Kaufmann

Germany

SS 12-4 Novel HPV testing methods

M. Poljak

Slovenia

SS 12-5 Meta-analyses on comparison of HPV tests for LSIL and ASCUS triage

M. Arbyn

Canada

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


33

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



&

HN

HPV and head & neck cancers: the key questions

Sala Verde

Chair: J. Lacau St Guily, G. D’Souza

12:45 - 14:00

SS 13-1 HPV detection methods in head & neck cancers

N. Schlecht

USA

SS 13-2 HPV in head & neck cancers epidemiology and impact on survival

G. D’Souza

UK

SS 13-3 HPV effect on survival and treatment in head & neck cancers

L. Licitra

Italy

SS 13-4 Why have HPV-positive OPC a more favorable prognosis?

R. Brakenhoff

The Netherlands

SS 13-5 The case for vaccination of boys for oral HPV

S. Pai

USA

C. Badoual

France

SS 13-6 Tumor microenvironnement in HPV+ squamous cell carcinoma

of the head and neck SS 13-7 Therapeutic vaccination for HPV OSCC

S. van der Burg The Netherlands

Discussion

S E M I NA R SEM 1

&

HN

HPV infection and associated cancers: prevention and counseling

Sala Verde 14:00 – 15:00

Chair: C. Fakhry, L. Licitra

SEM1-1 Considerations for prevention of HPV-driven HNC:

HPV-related vaccination and promising biomarkers

A. Kreimer

USA

SEM1-2 Considerations for potential methods of secondary prevention

C. Fakhry

USA

SEM1-3 Common behavioral questions about oral HPV acquisition and transmission G. D’Souza

UK

SEM1-4 Key messages for media on HPV-related head & neck tumors

Italy

Discussion


34

L. Licitra

T U E S DAY,

N OV E M B E R

5


HPV and head & neck cancers - from research to practice (1)

Sala Verde

Chair: R. Brakenhoff

17:00 – 18:15

OC 14-1 Prevalence and risk factors for oral HPV infection in young Australians OC 14-2 Prognostic value of human papillomavirus and squamous cell carcinoma

antigen in head and neck squamous cell carcinoma

OC 14-3 Smokeless tobacco increases aneuploidy in oral HPV 16 E6/E7

transformed keratinocytes

A. Antonsson

Australia

Z. Deng

Japan

J.

Finland

Rautava

OC 14-4 Effect of smoking habits on HPV status

and SLPI (Secretory Leukocyte Inhibitor) expression in head and neck cancer E. Quabius

OC 14-5 Human papillomavirus and cystic neck metastasis

in oropharyngeal carcinoma and unknown primary carcinoma

OC 14-6 Virological markers in HPV-driven oropharyngeal squamous cell carcinomas:

viral DNA methylation seems to be a promising prognostic marker

OC 14-7 Studies on the presence of human papillomavirus (HPV) and p53 expression

in neck metastasis with unknown primary in correlation to clinical outcome

OC 14-8 APTIMA HPV testing of fine needle aspirates, saliva and oral swabs

from patients with squamous cell carcinoma of the head and neck

OC 14-9 Human papillomavirus (HPV) DNA detection in different biological tissues

of patients with oral leukoplakia

OC 14-10 Impact of HPV genotype on clinical course

of juvenile onset recurrent respiratory papillomatosis

OC 14-11 Examining distress levels in patients with oropharyngeal versus

non-opropharyngeal squamous cell carcinomas of the head and neck

&

HN

Germany

T. Yasui

Japan

D. Barbieri

Italy

T. Ramqvist

Sweden

M. Chernesky

Canada

G. Miyahara

Brazil

P. Campisi

Canada

D. Hao

Canada

Discussion

OC 15

HPV and head & neck cancers - from research to practice (2)

Sala Verde

Chair: L. Licitra

18:15 – 19:30

OC 15-1 HPV prevalence in HNSCC in Queensland, Australia

A. Antonsson

Australia

OC 15-2 Prevalence and distribution of alpha and beta HPVs in the nasopharynx

B. Kocjan

Slovenia

OC 15-3 Oral HPV16 persistence among participants of the HPV infection

C. Pierce Campbell USA

in men (HIM) study

OC 15-4 Cytopathology and HPV testing in the detection of head and neck

squamous cell carcinoma

OC 15-5 The ICO study on HPV detection and genotype distribution

in head and neck cancers: results from the European region

OC 15-6 Genetic polymorphisms in miRNA genes and HPV status

as biomarkers for response in oropharyngeal cancer patients

OC 15-7 Improved survival from head and neck cancer in Denmark 1978-2010.

Focus on human papillomavirus associated tumors.

OC 15-8 Natural history and risk factors of oral HPV infection

in HIV-infected and HIV-uninfected women and men

OC 15-9 Incidence of HPV-associated tonsillar and base-of-tongue carcinomas

from the northern Netherlands over a 16 year period

OC 15-10 E6 oncoprotein as a marker for HPV induced cancers of the head and neck

&

HN

M. Benevolo

Italy

L. Alemany

Spain

K. De Ruyck

Belgium

M. Svahn

Denmark

D. Beachler

USA

E.. Schuuring

The Netherlands

J.

USA

Schweizer

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


35

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Low risk HPV infection and related diseases: the global picture Chair: M. Steben, C. Lacey

Limonaia 13:00 - 15:00

SS 14-1 LR vs. HR HPV infection – epidemiology – transmission

A. Giuliano

USA

SS 14-2 Molecular biology

J.

UK

SS 14-3 Disease burden

M. Steben

Canada

SS 14-4 The clinical picture

C. Lacey

UK

SS 14-5 Recurrent respiratory papillomatosis surveillance in Australia

J.

Australia

SS 14-6 Management of LR HPV-associated diseases

P. Mullerat

UK

SS 14-7 Treatment of anal condyloma and recurrence

S. Goldstone

USA

Doorbar

Brotherton

Discussion


SS 15

Therapeutic vaccines: looking into the future

Limonaia

Chair: M. Einstein, P. Stern

17:00 - 18:00

SS 15-1 Immune responses from therapeutic vaccines for HPV-associated cancers S. Van der Burg The Netherlands SS 15-2 Therapeutic effect of the prophylactic HPV vaccines

A. Kaufmann

Germany

SS 15-3 Innovations in therapeutic vaccine development

M. Safaeian

USA

SS 15-4 Initial results of Vicoryx a phase I/IIa study of immunization

with a p16INK4a derived peptide in patients with advanced HPV-associated cancers

M. von Knebel-Doeberitz Germany

SS 15-5 Safety, pharmacokinetics and efficacy phase II-a study of

AP611074, a HPV-specific treatment for anogenital warts

F.

Thierry

France

Discussion

SS 16

Anal HPV-associated diseases – the women's perspective

Limonaia

Chair: J. Palefsky, S. Goldstone SS 16-1 Anal HPV infection and anal neoplasia in HIV+ and HIV- women

18:00 - 19:15 J.

Palefsky

USA

SS 16-2 Screening approaches for anal squamous intraepithelial lesions in women P. Mullerat

UK

SS 16-3 Anal squamous intraepithelial lesions in HIV+ and HIV- women

A. Grulich

Australia

SS 16-4 Trends in anal cancer incidence in women and men

G. Clifford

France

S. Goldstone

USA

L. Siproudhis

France

SS 16-5 Current approaches to treatment of anal squamous intraepithelial lesions:

a 13 years experience SS 16-6 Evolution of anal dysplasia lesions within human immunodeficiency

virus positive patients screening. Discussion

36

T U E S DAY,

N OV E M B E R

5


Palazzo degli Affari

Screening (3): controversies in cervical cancer screening and prevention Priority setting for cervical cancer control: developed vs. developing countries

Ground floor 13:00 - 15:00

Chair: N. Schlecht, M. Jit SS 17-1 Introduction: how to integrate screening and vaccination

X. Bosch

Spain

SS 17-2 High income countries (HIC)

C. Meijer

The Netherlands

SS 17-3 Low and middle income countries (LMIC)

J.

USA

Cytology vs. HPV testing Smith

Cervical HPV screening: self-testing vs. medical professional testing SS 17-4 High income countries (HIC)

D. Heideman

The Netherlands

SS 17-5 Low income countries (LIC)

J.

USA

Belinson

2 vs. 3 doses schedule SS 17-6 High income countries (HIC)

M. Brisson


R. Sankaranarayanan France

Canada

School vs. health center based delivery SS 17-8 High income countries (HIC)

F.


S. Wang

Switzerland

SS 17-10 Improved screening vs. introduction of vaccination or both?

H. Berkhof

The Netherlands

Martinon-Torres Spain

Discussion


SS 18


Clinical value of p16

Ground floor Chair: M. von Knebel-Doeberitz, C. Bergeron SS 18-1 Update on the pathogenesis of HPV-induced cervical lesions

17:00 - 19:15 M. von Knebel-Doeberitz Germany

SS 18-2 p16INK4a as novel diagnotic stratificator to define low

and high grade lesions (the US perspective) SS 18-3 Current evidence for using p16

INK4a

in histology and cytology: a systematic meta-analysis of published reports

M. Stoler

USA

M. Reuschenbach Germany M. Arbyn Belgium

SS 18-4 Combined use of p16INK4a and Ki67 as biomarkers

in primary cervical screening SS 18-5 Combined use of p16I

INK4a

C. Bergeron

France

and Ki67 as biomarkers in cytology:

The US perspective

N. Wentzensen USA

SS 18-6 The use of p16IINK4a as triage tool for HPV-positive women

G. Ronco

Italy

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


37

EUROGIN

20 1 3

HPV

AT A CROSSROADS

T U E S DAY,

N OV E M B E R

5


HPV and other cancers - new insights


Chair: K. Syrjänen, M. Poljak

13:00 - 15:00

SS 19-0 HPV in head & neck cancer - epidemiology and impact on survival

H. Mehanna

UK

SS 19-1 Lung cancer

K. Syrjänen

Finland

SS 19-2 Esophageal cancer: any role of HPV?

M. Poljak

Slovenia

SS 19-3 Breast cancer

K. Syrjänen

Finland

SS 19-4 Prostate cancer

R. Tachezy

Czech Rep.

L. Lorenzon

Italy

G. Gross

Germany

SS 19-5 HPV and colorectal cancer: translating the molecular basis of the viral

associated carcinogenesis in colorectal cancerous tissues SS 19-6 Penile cancer

Discussion


SS 20

Epigenetics of cervical carcinogenesis


Chair: C. Meijer, N. Wentzensen

17:00 - 18:00

SS 20-1 Methylation of the HPV genome, differences between HPV types

N. Wentzensen USA

SS 20-2 Methylation analysis to improve cervical cancer screening

B. Wisman

The Netherlands

SS 20-3 Use of DNA methylation for screening of cervical and vaginal

self-collected specimens SS 20-4 Diagnostic classifiers based on HPV and human gene methylation

R. Steenbergen The Netherlands A. Lorincz

UK

M. Schmitz

Germany

SS 20-5 A DNA methylation signature that allows the triage of high-risk

human papillomavirus DNA-positive women Discussion

SS 21

HPV infection: from molecular biology to diseases


Chair: J. Doorbar, K. Shroyer

18:00 - 19:15

SS 21-1 HPV latency at the cervix and other anatomic sites

A.B. Moscicki

USA

SS 21-2 Latency molecular explanations and HPV expression

J.

UK

SS 21-3 Origins of cervical disease and biomarker selection

M. Herfs

USA

SS 21-4 Keratin 17 expression in cervical glandular and squamous neoplasia

K. Shroyer

USA

Doorbar

SS 21-5 Secondary alterations required for progression of early transformed lesion M. von Knebel-Doeberitz

Germany Discussion

38

W E D N E S DAY, N O V E M B E R

6


Vaccines (4): HPV vaccination of patients with diseases


Chair: E. Joura

8:00 – 9:30

CS 5-1

Effects of quadrivalent vaccine immunization in individual RRP patients

T. Fromm

Germany

CS 5-2

Potential mechanisms of post-exposure prophylaxis by HPV vaccines

A. Kaufmann

Germany

CS 5-3

Genital warts in males

S. Goldstone

USA

CS 5-4

Reduction of recurrent diseases after conization

E. Joura

Austria

CS 5-5

HPV types in recurrent diseases

O. Iversen

Norway

Discussion

MAIN SCIENTIFIC SESSIONS MSS 6 Epidemiology (2) of HPV infection


Chair: M. Goodman, G. Clifford

9:30 - 11:00

MSS 6-1 Sources of anogenital and oral HPV infection

M. Goodman

MSS 6-2 Heterosexual transmission: results from a short term observational study A.B. Moscicki

USA USA

MSS 6-3 Worldwide variations in age-specific HPV prevalence curves:

the driving role of sexual mixing

I.

Baussano

France

MSS 6-4 Estimation of human papillomavirus (HPV) transmissibility:

insights from mathematical modeling

M. Brisson

Canada

E. Velasco

USA

E. Shaw

Canada

A. Rositch

USA

MSS 6-5 Lack of concordance between oral and cervical HPV infection among

adult women in the USA: cross-sectional analysis of NHANES 2009-2010 MSS 6-6 Genital and reproductive health factors and HPV infection risk MSS 6-7 The impact of the 1965-1975 sexual revolution on female genital tract

high-risk human papillomavirus prevalence in the United States Discussion

MSS 7 EUROGIN 2014 ROADMAP


HPV infection in men, genito-anal vs. oral, convergences and divergences

Ground floor

Chair: A. Giuliano

11:00 - 12:30

&

HN

MSS 7-1 Introduction: overview of HPV infection in men across anatomic sites

and genital HPV natural history

A. Giuliano

USA

MSS 7-2 Anal HPV – men vs. women

A. Nyitray

USA

MSS 7-3 Oral HPV - men vs. women

A. Kreimer

USA

MSS 7-4 Compare transmission from male to female vs. female to male

M. Goodman

USA

MSS 7-5 HPV capsid antibody response – men vs. women

S. Sudenga

USA

MSS 7-6 Comparison of HPV-related disease in men and women

S. Franceschi

France

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


39

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



HPV testing methods (2)


Chair: A. Hesselink – H. Ikenberg OC 16-1 An analysis of the COBAS HPV test performance in US laboratories

12:30 – 14:00 J.

Engstrom-Melnyk USA

OC 16-2 Comparison of the CareHPV and Hybrid Capture-2 assays for

the detection of high-risk HPV genotypes in HIV-positive African women

M. N.Didelot-Rousseau France

OC 16-3 Point-of-care determination of high risk HPV infection using

OncoTect 3Dx® POC parameters and bioinformatics

A. Chargin

USA

T. Bourlet

France

H. Pedersen

Denmark

H. Ikenberg

Germany

OC 16-4 Comparative evaluation of the real-time PCR based LIPA assay for the

detection and the genotyping of human papillomavirus in cervical specimens versus CLART® HPV-2 micro array and conventionnal INNO-LiPA extra genotyping tests OC 16-5 Clinical and Analytical evaluation of the real-time PCR HPV assay on

SurePath samples from women with abnormal cytology OC 16-6 Comparison of a new PCR technique with gold standard signal

amplification HPV testing in routine

OC 16-7 Development of a single use genexpert catridge assay for HPV diagnostics L. Lindberg

Sweden

OC 16-8 Clinical validation of the papillocheck assay according to

international guidelines for HPV test requirements for cervical screening

A. Hesselink

The Netherlands

OC 16-9 Performance of the Onco E6 cervical test

in the start-up clinical study in rural China Discussion

40

M. Berard-Bergery USA

W E D N E S DAY,

N OV E M B E R

6


Vaccines (5): the post-vaccination era

Sala Verde

Chair: J. Brotherton, P. Bonanni

8:00 - 9:45

SS 22-1 Human papillomavirus prevalence following a national vaccination program S. Tabrizi

Australia

SS 22-2 Type replacement SS 22-3 Reduction of cytologic atypia and cervical procedures

J.

Paavonen

Finland

SS 22-4 Impact on screening participation

J.

Brotherton

Australia

SS 22-5 Decline in CIN in Australia due to vaccination: results of a data linkage study D. Gertig

Australia

SS 22-6 Evaluation of vaccine program effectiveness: a Nordic perspective

J.

Sweden

SS 22-7 Measures of vaccine effectiveness

S. Garland

Australia

SS 22-8 Comparison of Canadian and American systems in HPV prevention

M. Steben

Sweden

Dillner

Discussion

SS 23

Vaccines (6): other potential indications and other targets for HPV vaccination

Sala Verde

Chair: A. Grulich, X. Castellsagué

9:45 - 11:15

Rationale to vaccinate males: SS 23-1 - Genital SS 23-2 - Anal

A. Giuliano S. Goldstone

USA USA

SS 23-3 Populations at risk of HPV diseases

J.

USA

SS 23-4 Young adult women

X. Castellsagué Spain

SS 23-5 Immunosuppressed patients

A. Grulich

Australia

SS 23-6 Vulnerable populations

S. Garland

Australia

Palefsky

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


41

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Vaccines (2): prophylactic and therapeutic vaccines

Sala Verde

Chair: P. Sparen, C. Sauvageau

11:15 – 13:00

OC 17-1 Evaluating HPV vaccination strategies in Canada using cancer risk

management HPV microsimulation model (CRM-HPVMM)

C. Popadiuk

Canada

X. Bresse

France

J.

Colombia

OC 17-2 Towards the true value of universal HPV vaccination:

broadening the scope of benefits in evaluating vaccine OC 17-3 HPV6/11/16/18 vaccine efficacy in women 24 to 45:

follow-up through 6.3 years post-vaccination

Luna

OC 17-4 The participation of HPV-vaccinated adult women in a

national cervical screening programme in Sweden

E. Herweijer

Sweden

P. Sparén

Sweden

G. Sroczynski

Austria

S. De Sanjosé

Spain

OC 17-8 Serological surveillance of HPV immunisation in England

D. Mesher

UK

OC 17-9 Immune response to tipapkinogen sovacivec in CIN2/3 patients

M. Einstein

USA

S. Weyers

Belgium

F.

Germany

OC 17-5 HPV vaccination uptake in Sweden in opportunistic and

organized vaccination programs OC 17-6 Systematic evidence assessment for HPV vaccination in males

in the European health care context based on the grade method OC 17-7 Potential impact of a 9-valent HPV vaccine in invasive cervical cancer

in 4 emerging economies (Brazil, China, India and Mexico).

OC 17-10 Surveillance of effects of human papillomavirus immunisation

in Belgium (SEHIB): second interim analysis OC 17-11 Generation of chimeric p16

INK4a

-HPV16 L1 particles for second generation HPV vaccines

Faulstich

OC 17-12 Phase I study of p16

INK4a

peptide vaccination in patients with advanced human papillomavirus-associated cancer

M. Reuschenbach Germany

OC 17-13 HrHPV immunisation is associated with less CIN

data from the Scottish cervical screening programme. Discussion

42

T. Palmer

UK

W E D N E S DAY,

N OV E M B E R

6


Screening (4): screening in various situations are best practices linked to robust outcome data?

Limonaia

Chair: D. Harper, G. Ronco

8:00 – 9:30

Screening for special populations (I.S. – DES – History of CIN)

T. Wright

USA

CS 6-2

Screening of older women

D. Harper

USA

CS 6-3

Screening of vaccinated women

X. Bosch

Spain

CS 6-4

Screening following hysterectomy: is it relevant?

M. Cruickshank UK

CS 6-5

Directions for research

E. Franco

CS 6-1

Canada

Discussion


Cyto-histology

Limonaia

Chair: K. Syrjänen

9:30 – 11:15

OC 18-1 Biobanking of liquid based cytology – a validation study

M. Karlsson

Sweden

OC 18-2 Pittfalls of high-grade cytology

J.-P.Bogers

Belgium

D. Vale

Brazil

B. Andrae

Sweden

L. Baril

Belgium

OC 18-3 HSIL in women younger than 30 years shows

prevalence pattern resembling LSIL OC 18-4 Missing endocervical cells in screening does not imply an increased risk

of cervical cancer: a population based evaluation OC 18-5 Regression of cervical cytological abnormalities and CIN lesions

in the control cohort of the PATRICIA study OC 18-6 Atypical glandular cells in Pap test indicate precancerous or cervical cancer

in women under 50, and endometrial cancer in women over 50 years of age C. Asciutto OC 18-7 Typical glandular cells in screening implies a very high risk

of cervical carcinoma

Sweden

L. Arnheim Dahlström Sweden

OC 18-8 Six years experience in 180.000 cases with LBC and computer assistance

compared to conventional cytology OC 18-9 Impact of screening technology on cervical cytology results by age

H. Ikenberg

Germany

M.B.Franzmann

Denmark

K. Rozemeijer

The Netherlands

E. Kogan

Russia

M. Castellanos

USA

OC 18-10 Using SurePath in Dutch screening programme leads to increased CIN

detection rates as compared to ThinPrep or conventional cytology OC 18-11 Spheroid structures with stem cell-like phenotype in progression

of HPV-associated cervix uteri pathology OC 18-12 Diagnostic imaging of cervical intraepithelial neoplasia

through Hematoxylin and Eosin-derived fluorescence OC 18-13 Vulvar intraepithelial neoplasia: are we using

the most appropriate classification?

P. Vieira Baptista Portugal

OC 18-14 Two distinct morphogenetic units of the cervix and vagina

– lifelong clinical relevance

O. Reich

Austria

J.

USA

OC 18-15 Diagnostic and prognostic applications of p16 and HPV

in Oropharyngeal Squamous Cell Carcinoma

Zhai

Discussion

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


43

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30



Management options for women with HPV positive screening results

Limonaia

Chair: M. Stoler

11:15 – 12:45

CS 7-1

Biomarkers for triage of HPV+ women

N. Wentzensen USA

CS 7-2

Cytology

C. Meijer

The Netherlands

CS 7-3

Genotyping

M. Stoler

USA

CS 7-4

p16

C. Bergeron

France

CS 7-5

Reduction of colposcopy referrals through the use of screening tests and vaccination status

H. Berkhof

The Netherlands

Discussion

CS 8

Advanced topics on colposcopy and treatment

Limonaia

Chair: M. Roy

12:45 – 14:30

CS 8-2

Adenocarcinoma in situ: diagnosis, treatment and follow-up

M. Roy

Canada

CS 8-3

HPV genotype mapping of high-grade CINs in three morphological zones of cone specimens

K. Nielsen

Denmark

Colposcopic evaluation of HSIL cytology with negative hr-HPV tests rarely diagnoses endometrial cancer

R. Pretorius

USA

SEMM device for treatment of high-grade intraepithelial lesions of the uterine cervix: experience in a Brazilian university hospital

P. Naud

Brazil

Evaluation of the clinical performance of the COBAS® 4800 HPV test in a colposcopy referred population

C. White

Ireland

Surface distribution frequency and severity of cervical intraepithelial neoplasia in Chinese women

I.

USA

CS 8-8

Proportion of excision and pregnancy outcomes after LLETZ for CIN

E. Paraskevaidis Greece

CS 8-9

Outcomes of women with untreated CIN2 lesions: is there a role for HPV-related biomarkers?

M. Kyrgiou

UK

P. Hillemanns

Germany

A. Tristram

UK

CS 8-4 CS 8-5 CS 8-6 CS 8-7

Chang

CS 8-10 A placebo-controlled phase 2B study of hexaminolevulinate

photodynamic therapy in patients with CIN1 and CIN2 CS 8-11

A randomised trial of topical treatment for vulval intraepithelial neoplasia – preliminary clinical results Discussion

44

W E D N E S DAY,

N OV E M B E R

6


Cervical cancer control in low resource settings

Palazzo dei Congressi Room Onice

Chair: R. Sankaranarayanan

8:00 - 9:30

SS 24-1 Recent experiences on HPV vaccination in national immunization

programs and scaling-up of cervical screening in developing countries

R. Sankaranarayanan France

SS 24-2 Management options for screen positive patients in developing countries J.

Belinson

USA

SS 24-3 Different oncogenic HPV types in HIV positive than negative

South African women with cervical cancer SS 24-4 HPV Vaccination and cervical screening in Bhutan

M.C.Van Aardt

South Africa

U. Tshomo

Bhutan

SS 24-5 Reaching the unreachable : can HPV vaccination for cervical cancer

prevention be delivered to hard-to-reach populations in Kenya?

D. Watson Jones Tanzania

Discussion

COLPOSCOPY COURSE CC

Colposcopy course

Palazzo dei Congressi Room Onice

Coordinators: A. Singer, N. Pisal

9:30 – 15:30

Separate registration is required for this course This is a 6 hour intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out. 9:30

•

Registration

10:00

•

The normal Cervix: a prerequisite to understanding the abnormal cervix

A.

Singer

UK

10:25

•

How do we diagnose cervical precancer: pathology, HPV and biomarkers

A.

Singer

UK

11:00

•

Questions and discussion

11:10

•

Coffee

11:20

•

The abnormal cervix: colposcopy and methods of examination and video case presentations

A.

Singer

UK

12:30

•

Micro-invasive cancer and glandular disease: management

N.

Pisal

UK

12:55

•

Treatment of cervical precancer: who, why and how

N.

Pisal

UK

13:35

•

Coffee and cake

13:45

•

Interactive case presentations: cytology, colposcopy, pathology and treatment

A.

Singer

UK

N.

Pisal

UK

15:00

•

EUROGIN

Summary and Close

20 1 3

HPV

AT A CROSSROADS

- 30


45

EUROGIN

20 1 3

Italian

Novembre 4-5

Workshop

2013

WO R K S H O P I TA L I A N O ( I t a l i a n Wo r k s h o p ) Sulla base di precedenti esperienze in altri paesi europei e della richiesta da parte di diverse società scientifiche italiane,

nell'ambito del congresso EUROGIN internazionale 2013è stato organizzato uno "Workshop Italiano". Questo workshop è stato programmato e condiviso dalle società scientifiche italiane partecipanti e dalle organizzazioni che operano nel campo delle malattie correlate all'infezione da HPV. Gli argomenti trattati sono molto ambiziosi e comprendono gli aspetti di prevenzione primaria, la comunicazione, lo screening, la colposcopia e la ricerca con particolare attenzione alla situazione italiana. L'obiettivo del workshop è quello di promuovere lo scambio di esperienze e la condivisione della conoscenza a livello scientifico internazionale. Questo tipo di condivisione ha dimostrato di essere molto stimolante nei precedenti incontri.

IW 1

La comunicazione nell’era HPV

N OV

4

Chair: G. Amunni, P. Bonanni IW 1-1 IW 1-2 IW 1-3 IW 1-4 IW 1-5 IW 1-6 IW 1-7

IW 2

Lettura magistrale La comunicazione nella campagne vaccinali La comunicazione nello screening La comunicazione con la popolazione

P. Cristoforoni M. Conversano C. Cogo M.R.Gismondo

IW 2-6 IW 2-7 IW 2-8

Italy Italy Italy Italy

Oral Communications Immune responses to a 2-dose schedule of the HPV-16/18 as04-adjuvanted vaccine in girls (9-14) versus 3 doses in women (15-25): a randomised trial S. Esposito Italy The ASC-US in the cytology triage: category at risk? D. Butera Italy Cervical cancer risk in foreign women and equity of access to healthcare services and surgical treatment in the Reggio Emilia Province P. Giorgi-Rossi Italy Discussione plenaria

Malattie HPV correlate extra-cervicali

N OV

4

Chair: M. Barbero, P. Scirpa IW 2-1 IW 2-2 IW 2-3 IW 2-4 IW 2-5

Palazzo degli Affari First floor 14:15 - 15:30

Lettura magistrale La vaccinazione nelle patologie extra-cervicali La malattia vulvare La vaccinazione nel maschio HPV e dermatologia

M. P. C. L. G.

Oral Communications Recent advances in HPV-based immunotherapy of head and neck cancers with the help of green world Prevalence and molecular characterization of HPV-associated head and neck squamous cell carcinomas from Northern Italy Comparing biomarkers for tissue detection of HPV-associated oropharyngeal cancer Discussione plenaria

MSS 4 Cervical cancer control in Italy: screening and vaccination


N OV

5

Tommasino Castiglia Carriero Mariani Zuccati

Italy Italy Italy Italy Italy

A. Venuti

Italy

L. Baboci

Italy

P. Morbini

Italy

Palazzo dei Congressi Auditorium 9:30 - 11:00

Chair: F. Carozzi, A. Frega MSS 4-1 Best practices in Italy to get a good vaccine coverage

P. Bonanni P. L. Lopalco

Italy Sweden

MSS 4-2 HPV as primary screening: from research to practice

M. Zappa J. Cuzick

Italy UK

MSS 4-3 The clinician : towards the change in prevention

A. Perino S. Dexeus

Italy Spain

Discussant: Discussant: Discussant:

Discussion

46

Italian

Workshop

IW 3

Vaccinazione e screening

N OV

5

Chair: E. Paci, S. Guaschino IW 3-1 IW 3-2 IW 3-3 IW 3-4 IW 3-5 IW 3-6 IW 3-7

Lettura magistrale Il punto di vista della sanità pubblica Il punto di vista dei programmi di screening Il punto di vista del ginecologo

S. R. P. A.

Oral Communications Screening with primary HPV-DNA test: first results in women at the second screening round Is it time to shift to HPV as primary screening test? Defining priorities to improve cervical cancer screening. Vaccination in young adult women: preliminary results from ITT Tuscany trial Discussione plenaria

IW 4

La prospettiva del laboratorio tra screening e vaccinazione


N OV

5

Franceschi Gasparini Giorgi-Rossi Ciavattini


M. Zorzi

Italy

C. Naldoni

Italy

E. Burroni

Italy


Chair: D. French, G. Mojana IW 4-1 IW 4-2 IW 4-3 IW 4-4

Lezione magistrale La citologia di triage Organizzazione di un laboratorio HPV di grandi dimensioni Il type replacement : il ruolo del laboratorio

F. Carozzi M. Confortini M.T.Sandri E. Burroni

Oral Communications Comparison of the HC2 –hr results using QIAsymphony fully automated sample preparation and manualy convertion procedure for PreservCyt® specimens C. IW 4-6 The ONCLARITY™ HPV assay: evaluation of a new HPV test M. IW 4-7 Mucosal and cutaneous human papillomaviruses detected in raw sewages P. IW 4-8 Prevalence of genital warts in the Italian general female population B. IW 4-9 Cellularity control: key test for the evaluation of sample adequacy in the molecular diagnosis of HPV and other sexually transmitted diseases Z. IW 4-10 Human papillomavirus (HPV) infection in different anatomical sites of HIV-infected men M. Discussione plenaria


IW 4-5

IW 5

Protocollo di gestione nel follow-up post-trattamento e post colposcopia negativa

N OV

5

Sani Sandri Di Bonito Suligoi


Napoli

Italy

Martinelli

Italy


Chair: G. Amunni, P. Giorgi- Rossi IW 5-1 IW 5-2 IW 5-3 IW 5-4 IW 5-5 IW 5-6 IW 5-7 IW 5-8

Lezione magistrale Il protocollo Gisci Follow up con HPV test+ e Pap Il punto di vista del ginecologo Presentazione di alcuni casi clinici Quale test HPV nel follow-up Follow up del CIN I non trattato Follow up dell’AIS trattato

F. Boselli Italy T. Maggino Italy F. SopracordevoleItaly C. Penna Italy S. Costa Italy A. Del Mistro Italy C.A. Liverani Italy P. Cattani Italy

Oral Communications An on-line quality assurance programme for colposcopy in a population-based cervical screening setting in Italy: results on colposcopic impression P. Garutti IW 5-10 Hr-HPV testing in the follow-up of women with cytological abnormalities without CIN2+ lesions at the first colposcopy E. Burroni IW 5-11 Single and multiple HPV infection as risk factor for CIN2+: effect of age and HPV type. M. Sideri Discussione plenaria IW 5-9

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


Italy Italy Italy

47

EUROGIN

20 1 3

POSTERS P1

• HPV-6 variants detected in recurrent respiratory papillomatosis impacts upon viral early transcriptional activity

C. Bonfim

Brazil

• Is human papilloma virus associated with salivary gland neoplasms? An in situ hybridization study viral and molecular biology

L. Fadhel

Egypt

P 1-3

• Detection of human papillomavirus in placenta

A. Castillo

Colombia

P 1-4

• Utility loss with HPV-induced diseases in men and women

R. De Vincenzo Italy

P 1-5

• Oral administration of HPV-L6 L2 expressing lactobacillus casei induces systematic and mucosal cross-neutralizing effects in BALB/c mice

H. Poo

Korea

P 1-1 P 1-2

P2

Epidemiology & natural history

P 2-1

• Distribution and risk association of HPV52 variant lineages worldwide

P. Chan

Hong Kong

P 2-2

• Prevaccination prevalence and distribution of high-risk human papillomavirus (HR-HPV) types in Montengrian women

D. Vujosevic

Montenegro

P 2-3

• The increasing incidence of cervical cancer in young women in Korea

K.-T. Kim

Korea

P 2-4

• HPV-induced cervical lesions in young Brazilian population - analysis of cervical biopsies between 2007 and 2011

D. Monteiro

Brazil

• Distribution and vertical transmission of vaginal infections in pregnant women without vaginal symptoms

K.-T. Lim

Korea

• The prevalence of human papillomavirus in cervical swab samples: Korean prospective multicenter study

K.-J. Min

Korea

• Prevalence and distribution of human papillomavirus infection in Arab women in state of Qatar

D. Bansal

Qatar

P 2-8

• Frequency of HPV high and low risk in Brazilian samples

A. Alfieri

Brazil

P 2-9

• HPV status in menopausal women. is cervical screening by cytology enough? L. Michala

Greece

P 2-10

• HIV prevalence in women with HPV 16 and 18 infection in Galicia, Spain.

A. Cid

Spain

P 2-11

• The relationship between prevalence and genotyping of human papillomavirus 16/18 with cervical abnormalities by age groups

V. Saddi

Brazil

P 2-5 P 2-6 P 2-7

P 2-12

• Genital HPV infection and progression to external genital lesions: the HIM study S. Sudenga

P 2-13

• Prevalence of human papillomavirus and hrHPV E6/E7 mRNA expression in 52 Greek patients with SCC of the oral tongue

USA

E. Panotopoulou Greece

P 2-14

• Monitoring HPV type prevalence in the post vaccination era in women living in the Basilicata region, Italy L. Serradell-Vallejo France

P 2-15

• HPV infection in HIV positive women vaccinated with a quadrivalent HPV vaccine E

P 2-16

• The distribution of high-risk human papillomavirus genotype in high-grade cervical intraepithelial neoplasia of Korean women

J. H. Kim

Korea

• Anal HPV prevalence and anal cytology among HIV-infected and HIV-uninfected men who have sex with men

M.G.Dona

Italy

P 2-17

48

Viral, molecular biology, pathogenesis and immunology

Moses

USA

POSTERS

POSTERS • Using a system dynamics simulation model to determine human papillomavirus vaccination effectiveness

N. Schlecht

USA

P 2-19

• HPV positivity in triple-negative breast cancers

A. Piana

Italy

P 2-20

• Prevalence of HPV and chlamydia trachomatis infections in undocumented immigrant women in Milan, Italy

E. Frati

Italy

P 2-18

P3

HPV vaccines

P 3-1

• Migraine following human papillomavirus (HPV) vaccination

T. van 't Klooster The Netherlands

P 3-2

• The Italian “call centre project” for HPV-vaccination: preliminary results from the pilot experience in Calabria region and Genoa

R. Tosatto

P 3-3

• Universal vaccination against 6/11/16/18 HPV-related diseases in Sweden: towards HPV disease control? M. Adam

Italy France

P 3-4

• Romanian HPV vaccination status: June 2010 - June 2013

O. Streinu-Cercel Romania

P 3-5

• Persistence of immune response 7 years after administration of the HPV-16/18 AS04-adjuvanted vaccine to women aged 15–55 years’

T. Schwarz

Germany

• Description of the adherence level of vaccination against human papilloma virus (HPV) in a university population (São Paulo – Brazil)

L. Hime

Brazil

• Clinical trial PHASE III B: effect of vaccination in patients with RRP – enrollment data

J.

Smahelova

Czech Republic

P 3-8

• HPV infection in girls vaccinated in the Czech Republic

E. Hamsikova

Czech Republic

P 3-9

• HPV-vaccination coverage five years after introduction: first German population estimates for 14 to 17 year old girls.

C. Poethko-MüllerGermany

• Vaccination against gynecological cancer: from new opportunities to new horizons

V. Prilepskaya

P 3-6 P 3-7

P 3-10

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


Russia

49

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


POSTERS P4 P 4-1

• Sensitivity of three commercial PCR-based assays for the detection of human papilloma virus in a dilution study

P 4-2

®

A. Hammer

Denmark

• Analytical evaluation of APTIMA HPV performance with SurePath liquid-based cytology specimens using the APTIMA transfer solution

B. Weinbaum

USA

• Clinical performances of Bio-Rad Dx hr-HPV auto assay for detection of high-grade cervical intraepithelial neoplasia.

P. Sednaoui

France

• Comparison between nested and single-step PCR for high-sensitivity detection of human papillomavirus

S. Mason

Italy

• Aptima HPV mRNA assay is as sensitive but more specific than linear array HPV genotyping test for post-treatment surveillance

M. Waldstrøm

Denmark

• HC2 versus Cobas HPV test in SurePath samples from women aged ≥30 years with ASCUS

D. Fornari

Denmark

• Incident HPV infection at 48 month exit screen among women in the HPV focal trial

E. Franco

Canada

• Assessing the role of a novel panel of mRNA biomarkers for managing women in colposcopy

P. Tewari

Ireland

• Prospective study evaluating the role of HPV mRNA-testing in the management of cervical lesions caused by hr-HPV

R. De Vincenzo Italy

P 4-10

• The role of HPV viral load in patients with ASCUS or LSIL

H.J. Suk

Korea

P 4-11

• Comparison of high risk HPV testing and genotyping by APTIMA assays with the digene HC2 platform on anal ThinPrep specimens

M. McCoy

USA

• Comparison of INNO-LiPA HPV genotyping and Hybrid Capture-2 (HC2) assays for the detection of high-risk HPV genotypes and cervical intra-epithelial neoplasia in HIV-positive African women: HARP study

C. Gilham

UK

• APTIMA transfer solution pretreatment of SurePath samples using heat and enzyme before testing by APTIMA HPV compared to cobas 4800 HPV

M. Chernesky

Canada

• NucliSENS-EasyQ mRNA-assay as a triage test after detection of HPV 16/18/31/33/45 DNA in ASCUS

S. Perez

Spain

• The potential use of direct E6/E7 HPV whole-cell ELISA™ for triaging patients with high-risk HPV positive ASC-US or LSIL cytology

S. Cheng

USA

• Comparison between two commercially available methods for molecular detection of high risk HPV.

N. Gaburo

Brazil

P 4-3 P 4-4 P 4-5 P 4-6 P 4-7 P 4-8 P 4-9

P 4-12

P 4-13 P 4-14 P 4-15 P 4-16

P5 P 5-1 P 5-2 P 5-3

50

HPV testing

®

Genotyping • The role of HPV genotyping, p16/Ki-67 dual stain and koilocytosis in the prediction of cervical low-grade squamous intraepithelial lesions

D. Vrdoljak-Mozetic Croatia

• Evaluation of the novel ANYPLEXTM II HPV28 genotyping assay for diagnosis and typing of HPV from archival clinical samples

G. Helenius

Sweden

• Optimization of reporting genotypes with overlapping hybridization pattern by INNO-LiPA HPV genotyping extra

E. Padalko

Belgium

POSTERS

P6

Molecular markers

P 6-1

• HPV E6II gene expression as an indicator of cancer severity in intraepithelial cervical lesions of uterine cervix – a pilot study.

P 6-2

• P16 in endometrial cancer and its possible correlation to human papillomavirus D. Freund

Denmark

P 6-3

• CIN regression is higher in small HPV16+ lesions and in HPV16- lesions of patients that consistently used condoms

A.C. Munk

Norway

• Methylation of liquid based cervical cytology infected with human papillomavirus type 16 DNA according to the degree of cervical pathology

E.Y. Ki

Korea

P 6-5

• Dynamin inhibitors as anti-cancer agent in cervical carcinoma

B.G.Kim

Korea

P 6-6

• HPV E6/E7 messenger RNA as a marker for non-recurrence of CIN after conisation?

L. Pandiani

France

P 6-7

• Leucine-rich immunoglobulin-like repeats (LRIG) 1, 2 and 3 in cervical neoplasia A. Lindström

P 6-8

• Association between dual staining and cervical epithelial abnormalities induced by HPV infection

I.

Krivak-Bolanca Croatia

P 6-9

• Silencing HPV16 E6 oncogene in a cervical cancer cell model

I.

Soyingbe

P 6-10

• Construction of bio-sensors with composite peptide–dendrimers to detect E6 oncoprotein in lesions progressing to cervical cancer

G. Zaldivar

Mexico

• Evaluation of a diagnostic method for cervical cancer: non-coding mitochondrial RNAs as markers

J.

Villegas

Chile

• Expression of MMP-2, MMP-9, MMP-14, TIMP-1 and TIMP-2 in the intraepithelial and invasive cervical neoplasia.

L.C.Zeferino

Brazil

• Significance of p16 immunostaining in postmenopausal women with atypical squamous cells

A. Repse-Fokter Slovenia

• Detection of chromosomal changes in regions 3q26 (hTERC) and 8q24 (MYCC) in precancers and carcinoma of the uterine cervix

L. Moukova

Czech Republic

• Immunome profiling: a powerfool tool for diagnostics and therapeutics

K. Joers

Estonia

P 6-4

P 6-11 P 6-12 P 6-13 P 6-14 P 6-15

P7

A. Kamer-Bartosinska Poland

Sweden

Ireland

Screening methods • A randomised controlled trial of response to self-sampling for HPV in persistent non-responders in Newcastle upon Tyne , UK (the SHINE trial) L. Cadman

UK

• Can women who have had a hysterectomy due to non-malignant indications be excluded from cervical cancer prevention activities?

E. Wallgard

Sweden

P 7-3

• p16INK4a/Ki67 vs. HPV testing for triage of LSIL

C. Sousa

Portugal

P 7-4

• Improving attendance to the cervical cancer screening program in Norway: pilot study for self-sampling K. Schee

Norway

• Comparison of the PapilloCheck and INNO-LiPA HPV genotyping extra assays for HPV detection and typing

F.

Najioullah

France

P 7-6

• Can HPV test replace cytology in cervical cancer screening?

N. Fayzullina

Russia

P 7-7

• Cyto-histological concordance in LSIL and HSIL pap smears - 5 years experience

A. Pacheco

Portugal

P 7-8

• Cervical cancer screening in a public health center: a 5 years experience

A.M.Souza

Brazil

P 7-9

• Pap smear and cervical histology after short time repeat high-risk HPV testing K. Sanner

P 7-1 P 7-2

P 7-5

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


Sweden

51

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


POSTERS P8 P 8-1 P 8-2

P9 P 9-1 P 9-2

• Triage of women with ASC-US/LSIL cytology - the added value of implementation of an HPV-test

M. Msomphora Norway

• Colposcopy utilization following primary HPV screening with cytology triage

A. Coldman

Canada

• A pilot study to investigate the efficacy of fibrin sealant (TISSEEL®) in loop electrosurgical excision procedure (LEEP)

J. H. Kim

Korea

• Recurence of cervical intraepithelial neoplasias after conization – persistent HPV infection and smoking at risk factors

R. Zivadinoviç

Serbia

Anogenital neoplasia

P 9-3

• Anti-cancer effect of bee venom toxin and melittin in uterine cervical cancer cells M.J.Song

Korea

P 9-4

• Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia M. Jentschke

Germany

P 9-5

• Human papillomavirus in intraepithelial neoplasia and carcinoma of the vulva D. Cochicho

Portugal

P 9-6

• Prevalence, distribution and physical status of HPV in anal squamous cell carcinoma

K. Fujs Komlos Slovenia

• Liquid based cytology and vulvar intraepithelial neoplasia (VIN): is there any correlation?

M. Beldi

P 9-7

P 10 P 10-1

Brazil

Oral HPV infection • Oral HPV infection among men attending a sexually transmitted infection clinic in Puerto Rico

V. Colón López Puerto Rico

• Indication of planned neck dissection for oropharynx squamous carcinoma by positron emission tomography and human papillomavirus infection M. Hasegawa

Japan

P 10-3

• HPV related cervical disease and oropharyngeal cancer: a case report

S. Corioni

Italy

P 10-4

• HPV in prognosis and therapy of oropharyngeal cancer

H. Binkova

Czech Republic

P 10-2

52

Colposcopy

POSTERS

POSTERS P 11 P 11-1

HPV and oropharynx • Human papillomavirus load and physical status in sinonasal inverted papilloma and squamous cell carcinoma

M. Suzuki

Japan

P 11-2

• HPV association in malignant transformation of sinonasal inverted papilloma C. Masumura

Japan

P 11-3

• P16INK4a protein expression in oropharyngeal tract related to radiotherapy follow-up

M.A.Caponio

Italy

• Keratin 17 may be a novel prognostic marker independent of HPV status for head and neck squamous cell carcinomas

L. Shroyer

USA

P 11-5

• Human papillomavirus in lesions from head and neck region

D. Cochicho

Portugal

P 11-6

• Detection of oncogenic viruses in neck metastasis from occult SCC another HPV associated cancer?

F.

Italy

P 11-7

• Are cutaneous HPVs involved in oral cavity cancer?

B. Pichi

Italy

P 11-8

• Oral and genital HPV infection of asymptomatic men participating Finnish family HPV (FFHPV) study

K. Kero

Finland

C. Fodero

Italy

N. Luo

Singapore

P 11-4

P 12 P 12-1

HPV and other neoplasia • High-risk HPV infection in bilateral conjunctival squamous cell carcinoma and uterine-cervix: a case report

P 13 P 13-1 P 13-2

Bussu

Genital warts • Differential humanistic burden of genital warts in male and female patients in Asia

• Frequency of ano-genital warts among males in three cities of northern Italy B. Suligoi

P 14

Italy

Sexually transmitted diseases • Population-based prevalence and risk factors for bacterial vaginosis and other vaginal pathogens in young women in Germany

Y. Deleré

Germany

• Prevalence of human papillomavirus and cervical cytological abnormalities among HIV women: the role of immunossuppression

L. Machado

Portugal

P 14-3

• Chlamydia trachomatis genital infection: prevalence and risk factors

G. Kondo

Brazil

P 14-4

• High-risk HPV viral loads and chlamydia trachomatis co-infections in women with low-grade cervical dysplasia

C. Cocuzza

Italy

• Lymphogranulome venereum: case report

L. Hime

Brazil

P 14-1 P 14-2

P 14-5

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


53

EUROGIN

20 1 3

HPV

AT A CROSSROADS

- 30


POSTERS P 15 P 15-1 P 15-2 P 15-3 P 15-4 P 15-5

P 16 P 16-1 P 16-2 P 16-3

P 16-4 P 16-5 P 16-6 P 16-7

54

Conventional and new therapies • Recurrence after surgery due to cervical cancer an evaluation of the offered follow-up program

K. Fuglsang

Denmark

• Conservative treatment of cervical adenocarcinoma in situ is safe in women, who want to preserve their fertility.

B. Iwersen

Denmark

• The overtreatment risk of see-and-treat strategy in management of abnormal cervical cytology

W.Y. Kim

Korea

• Co2 laser total superficial vulvectomy for wide multifocal vulvar intraepithelial neoplasia grade 3: a case report.

C. Bianchi

Italy

• An intracellular single-chain antibody fragment for the therapy of human papillomavirus-associated tumors

P. Di Bonito

Italy

• Factors associated with mothers’ intention to get daughters vaccinated human papillomavirus in Korea

H.W.Kim

Korea

• The human papillomavirus: attitudes & behaviours toward the HPV vaccination & condom use, in relation to cancer prevention in males

S. Fitzgerald

Ireland

Advocacy, acceptability, psychology and health education

• Attitudes towards cervical screening, HPV testing and self-collected samples in the cervical screening context: a mixed methods study of hindu women in London

L. Ashdown-Barr UK

• Parents’ thoughts regarding their consent to HPV vaccinate their young daughter in a school-based vaccination programme

M. Gottvall

Sweden

• Knowledge of HPV infection and vaccine acceptability among males attending a sexually transmitted infection centre

M. Giuliani

Italy

• Knowledge, attitude and practice about cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of Congo C. Ali-Risasi

D. R. of Congo

• Education efforts to drive uptake of HPV vaccination in Singapore

Singapore

J. Y. Koh